Contract services experts at this week’s CPhI Discover – (17-28th May, 2021) – the largest ever online pharma event featuring content in the opening week and networking in week two – point to pandemic contracts delivering a significant boon to the CDMO sector, but forewarn of exacerbated shortages for viral vector manufacturing.
In a dedicated session three experts – Peter Shapiro Senior Director of Drugs and Business Fundamentals, PharmSource, a GlobalData Company; Eric Langer, President and Managing Partner, BioPlan Associates; and Kevin Sharp, Head of Alliance Management, Samsung Biologics – explore how the pandemic has quickly change the modus operandi of CDMOs, with greater forward planning and more rapid capacity increases, but also longer and more strategic contracts than before.
According to PharmSource’s Shapiro, while CDMOs have been undeniably big winners in the search for rapidly available capacity – particularly the largest players in the industry – the resultant effect is that we will now face shortages in other areas moving forwards:
“When we look at the rates of outsourcing for the products for COVID-19 given emergency use authorisations, we see 50% of these drugs had an associated contract manufacturing agreement and that includes all of the vaccines that were approved under EUA.”
However, Shapiro also predicted that, looking to the future, there would continue to be capacity problems in injectable dose and viral vector production – crucial to cell and gene therapy and now recombinant vector vaccines, which are being used against COVID-19.
“There was already a significant shortage of capacity in this field, and this has been exacerbated by the AstraZeneca and Johnson & Johnson vaccines as well as those from Russia and China,” added Shapiro.
Commenting on the overall impact of the pandemic response on biopharma development and manufacturing, and in particular on the CDMO market, Eric Langer of BioPlan Associates said there had been no real significant or dramatic shift, but instead we’ve seen an acceleration of what’s been there for 30 years.
“The industry is now seeing more facilities, more modular construction, and greater staff shortages, and that the pandemic has exacerbated short supply of single use products and devices, an issue that was predominant before the coronavirus outbreak,” Langer added.
In the longer-term, continuous bioprocessing and process intensification were highlighted by Langer as growth manufacturing strategies, with the pandemic proving the need to be able to rapidly respond to something that is obviously life threatening. Consequentially, all three experts suggested we may see contingency capacities now set aside by government or larger player in case of surge demand.
Highlighting the growing prominence of secure supply networks in CDMO contractual planning Samsung’s Sharp, added: “Within a very short period we saw that capacity dry up; whether it was internal capacity within the pharmaceutical company space or the CDMO industry available capacity and it was really agnostic to scale. Therefore, having flexibility from your CDMO to adjust to growing demand will be essential to maintaining commercial volumes. So, ensuring the long-term availability of required capacity at the CDMO when negotiating a commercial supply agreement is critical.”
The experts also suggested that the industry needs to zoom out and consider that the pandemic is not the only life-threatening challenge. Langer concluded: “All the clinical issues that we saw, whether it be in oncology, products being brought to market or the R&D associated with that, it doesn’t go away. People are literally dying as a result of the shift in focus from what had been before to the pandemic. This is a double hit on an industry that’s truly critical to so many people and the fact that we’re seeing it rise to the occasion is a tribute to the people involved in it.”
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; Finished Dosage Formulation for every aspect of the finished dosage supply chain; and NEX for natural extract products, applications and solutions.
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
